Recent News

Nivolumab Plus Cabozantinib Approved by FDA for Advanced Renal Cell Carcinoma

JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC

Immunotherapy After Nephrectomy Under Study in Localized Renal Cell Carcinoma

Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update

Avelumab Plus Axitinib Under Study in Urothelial Cancer

Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC

Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL

Preclinical Trial Explores Anti–PD-1 Strategies for Triple-Negative Breast Cancer

Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?

Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma

Combination Immunotherapy for Urothelial Carcinoma: Phase Ib Interim Analysis

Case Study of Rare but Aggressive Immune-Related Adverse Events in Kidney Cancer

Trop-2 Expression and Sacituzumab Govitecan in Triple-Negative Breast Cancer

Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: OMNIVORE Trial

ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma

DDR Alterations and Outcomes With Immunotherapy for Advanced Urothelial Cancer

SABCS 2020: Pembrolizumab Plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma

IL-7 After Sipuleucel-T for Advanced Prostate Cancer

Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity

JAVELIN Bladder 100: Avelumab Maintenance for Advanced Urothelial Carcinoma

Novel Chemoimmunotherapy Regimen Under Study in Recurrent Ovarian Cancer

ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma

ADP-A2M10 Dose-Escalation Trial in MAGE-A10–Positive Urothelial Tumors

Ramucirumab Plus Osimertinib in NSCLC: Final Analysis of Phase I Trial

ASH 2020: PI3K Inhibitor Plus Monoclonal Antibody Versus Chemoimmunotherapy for CLL

Potential Predictive Markers and/or Therapeutic Targets in Merkel Cell Carcinoma

HER2-Targeting Antibody-Drug Conjugate in Advanced Urothelial Carcinoma

ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma

ASH 2020: Early Results in Targeting CD47 in AML

FDA Brief: Eprenetapopt Given Fast Track Designation for TP53-Mutant AML

ESMO Asia 2020: MONARCH 2 Update on Abemaciclib Plus Fulvestrant in East Asian Patients With Breast Cancer

ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma

Are High 12-Chemokine Scores Prognostic in Muscle-Invasive Bladder Cancer?

Immunochemotherapy for Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort B Update

Neoadjuvant Ipilimumab Plus Nivolumab Under Study in Urothelial Carcinoma

ESMO Asia 2020: Subgroup Analysis of KEYNOTE-522 Supports Use of Pembrolizumab in Triple-Negative Breast Cancer

SITC 2020: Tumor Mutation Burden and Response to Immunotherapy in Advanced Urothelial Cancer

SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma

SITC 2020: Checkpoint Inhibitor Pair Tested in Thyroid Malignancies